文献速递艾滋病与性传播感染

多拉韦林/伊斯拉曲韦(100/0.75 mg)每日一次对比比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺作为HIV-1初始治疗的48周III期随机对照双盲非劣效试验结果

Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial.
PubMed 文献 · Clin Infect Dis · 2025-01-01

这项III期双盲双模拟非劣效试验将597例既往未治疗的HIV-1成人按1:1随机分配至多拉韦林/伊斯拉曲韦(100/0.75 mg)或比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺(50/200/25 mg)每日一次口服。第48周HIV-1 RNA<50 copies/mL的比例分别为88.9%与88.3%(差值0.5%,95%CI -4.7至5.6),达到非劣效。但因其他伊斯拉曲韦研究中观察到CD4和淋巴细胞计数下降,该剂量多拉韦林/伊斯拉曲韦的研发已停止。

要点

  • 多拉韦林/伊斯拉曲韦100/0.75 mg每日一次第48周疗效非劣效于比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺。
  • 多拉韦林/伊斯拉曲韦组CD4计数平均变化+182 cells/µL,低于对照组的+234 cells/µL(差值-50,95%CI -79至-21)。
  • 因CD4和淋巴细胞计数下降,该剂量多拉韦林/伊斯拉曲韦的研发已停止。

核心结论

  • 多拉韦林/伊斯拉曲韦(100/0.75 mg)每日一次至第48周在HIV-1初始治疗中非劣效于比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺。
  • 由于CD4和淋巴细胞计数下降,该剂量多拉韦林/伊斯拉曲韦的研发已停止。

研究设计与样本

  • III期、双盲、双模拟、随机、对照、非劣效试验(ClinicalTrials.gov NCT04233879)。
  • 既往未治疗的HIV-1成人按1:1随机,按HIV-1 RNA(≤/>100 000 copies/mL)和CD4计数(</≥200 cells/µL)分层,接受多拉韦林/伊斯拉曲韦(100/0.75 mg)或比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺(50/200/25 mg)每日一次口服。
  • 主要终点为第48周HIV-1 RNA<50 copies/mL的参与者百分比(美国食品药品监督管理局快照法,10%非劣效界值)。
  • 共597例参与者接受治疗;因其他伊斯拉曲韦研究中观察到CD4和淋巴细胞计数下降,入组提前停止。

主要发现

  • 第48周HIV-1 RNA<50 copies/mL:多拉韦林/伊斯拉曲韦组265/298(88.9%)vs 比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺组264/299(88.3%),差值0.5%(95%CI -4.7至5.6)。
  • CD4计数自基线平均变化:多拉韦林/伊斯拉曲韦组+182 cells/µL vs 比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺组+234 cells/µL(差值-50,95%CI -79至-21)。
  • 淋巴细胞计数平均变化:多拉韦林/伊斯拉曲韦组0.01×10^9/L vs 比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺组0.21×10^9/L(差值-0.20,95%CI -0.30至-0.10)。
  • 不良事件发生率:多拉韦林/伊斯拉曲韦组90.6% vs 比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺组87.3%,最常见为新型冠状病毒病2019(14.1% vs 16.4%)。
  • 治疗相关不良事件相似(28.9% vs 25.8%);导致停药的不良事件在多拉韦林/伊斯拉曲韦组更高(8.7% vs 3.7%),系因方案规定CD4和淋巴细胞计数下降需停药的标准。

关键数值与推荐

  • 主要终点非劣效界值为10%(美国食品药品监督管理局快照法)。
  • 第48周HIV-1 RNA<50 copies/mL差值0.5%(95%CI -4.7至5.6),达到非劣效。
  • CD4计数平均变化差值-50 cells/µL(95%CI -79至-21)。
  • 淋巴细胞计数平均变化差值-0.20×10^9/L(95%CI -0.30至-0.10)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 因其他伊斯拉曲韦研究中观察到CD4和淋巴细胞计数下降,入组提前停止。
  • 方案规定CD4和淋巴细胞计数下降需停药,导致多拉韦林/伊斯拉曲韦组因不良事件停药率更高(8.7% vs 3.7%)。
  • 由于CD4和淋巴细胞计数下降,该剂量多拉韦林/伊斯拉曲韦的研发已停止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Doravirine/islatravir is an investigational regimen that is being studied for human immunodeficiency virus type 1 (HIV-1) treatment. METHODS: In this phase 3, double-blind, double-dummy trial (ClinicalTrials.gov NCT04233879), previously untreated adults with HIV-1 were randomized (1:1) and stratified by HIV-1 RNA (≤/>100 000 copies/mL) and CD4 count (</≥200 cells/µL) to doravirine/islatravir (100/0.75 mg) or bictegravir/emtricitabine/tenofovir alafenamide (50/200/25 mg) orally once-daily (primary endpoint: percentage of participants with HIV-1 RNA <50 copies/mL at week 48; US Food and Drug Administration snapshot, 10% noninferiority margin). RESULTS: Overall, 597 participants were treated; enrollment stopped early due to decreases in CD4 and lymphocyte counts observed in other islatravir studies. Doravirine/islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide: 265 of 298 (88.9%) versus 264 of 299 (88.3%) had HIV-1 RNA <50 copies/mL (difference, 0.5%; 95% confidence interval [CI]: -4.7, 5.6). Mean change from baseline in CD4 count was +182 and +234 cells/µL (difference, -50; 95% CI: -79, -21) with doravirine/islatravir versus bictegravir/emtricitabine/tenofovir alafenamide. Mean change in lymphocyte count was 0.01 and 0.21 × 109/L (difference, -0.20; 95% CI: -0.30, -0.10). Adverse events (AEs) occurred in 90.6% and 87.3% of participants, with coronavirus disease 2019 being most common (14.1%, 16.4%). Treatment-related AEs were similar (28.9%, 25.8%). AEs that led to discontinuations were higher with doravirine/islatravir (8.7%, 3.7%) due to protocol-specified criteria that required discontinuation for decreased CD4 and lymphocyte counts. CONCLUSIONS: Doravirine/islatravir (100/0.75 mg) once-daily was noninferior to bictegravir/emtricitabine/tenofovir alafenamide through week 48 for initial HIV-1 treatment. Due to decreases in CD4 and lymphocyte counts, development of this dose of doravirine/islatravir was stopped. CLINICAL TRIALS REGISTRATION: NCT04233879.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rockstroh JK, Paredes R, Cahn P, et al. Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial. Clin Infect Dis. 2025. PMID: 40079835. doi:10.1093/cid/ciaf077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。